showed that mogamulizumab eliminated EBV+T cells in peripheral blood along with CCR4-expressing Tregs, thereby reducing its inhibition of tumor immunity in the body, and had a favorable impact on the tumor immune microenvironment (22). Here, CCR4 is linked to neoplasm.